GALMED PHARMACEUTICALS news, videos and press releases
For more news please use our advanced search feature.
GALMED PHARMACEUTICALS - More news...
GALMED PHARMACEUTICALS - More news...
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
- Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
- Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
- Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
- Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
- Thinking about buying stock in Healthcare Triangle, Galmed Pharmaceuticals, Express, Kartoon Studios, or Aeroports de Paris?
- Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
- Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
- Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
- Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
- Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
- Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
- Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
- Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
- Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects
- Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
- Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
- Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2
- Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
- Thinking about buying stock in Zynga, Reviva Pharmaceuticals, Molecular Partners, Galmed Pharmaceuticals, or Playtika?
- Galmed announces positive results of Phase 1 study of Amilo-5MER
- Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
- Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement
- Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
- Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
- Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound